Table 1.
Summary of results from studies reporting anti-HCV prevalence in the general population
| Author, year | Country | Recruiting period | Population as reported | Age, mean (SD) | Sample size | Anti-HCV prevalence (%) (95% CI) | Risk of selection bias |
|---|---|---|---|---|---|---|---|
| Viejo, 2018 [19] | Spain | February–April 2017 | The general adult population living in the health area of Callosa D’En Sarrià | 47.5 (−) | 2637 | 1.14 (0.73–1.55) | High risk |
| Lavin, 2017 [20] | Spain | 2015–2016 | Spanish adult population | – | 6839 | 1.11 (−) | Low risk |
| Quesada, 2015 [21] | Spain | 1994–2005 | Women from the general population in different geographical areas worldwide | 40.0(15.6) | 314 | 0.60 (0.20–2.50) | High risk |
| Andriulli, 2018 [22] | Italy | 2015 | The general population | – | 4907 | 2.30 (−) | Low risk |
| Morisco, 2017 [23] | Italy | May 14 | A random 1:3 systematic sample of the adult general population of Naples | 49.9(5.00) | 1315 | 3.00 (2.10–4.00) | Low risk |
| Walewska-Zielecka, 2017 [24] | Poland | 2004–2014 | Patients who had been tested for anti-HCV at least once in the period from 2004 to 2014 | 34.4(8.6) | 61805 | 1.50 (−) | High risk |
| Clifford, 2017 [25] | Poland | 2004–2009 | The general female population | 37.0(−) | 909 | 0.80 (0.30–1.60) | High risk |
| Garvey, 2017 [26] | Ireland | April–June 2014 and November 2015–February 2016 | The adult population in Ireland with probability proportional to the general population age-sex distribution | – | 3759 | 0.98 (−) | Low risk |
| Chlibek, 2017 [27] | Czech Republic | February 2015–September 2015 | The adult general population | 47.1(17.1) | 3000 | 1.67 (1.27–2.19) | High risk |
| Carvalhana, 2016 [28] | Portugal | April 2012–December 2014 | Adults from primary care settings in mainland Portugal | 50.2(18.3) | 1627 | 0.54 (0.20–0.90) | Low risk |
| Plompen, 2015 [29] | Netherland | − | The general Dutch elderly population | 69.5(9.0) | 6036 | 0.56 (−) | High risk |